GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocata Therapeutics Inc (NAS:OCAT) » Definitions » E10

Ocata Therapeutics (Ocata Therapeutics) E10 : $-26.52 (As of Sep. 2015)


View and export this data going back to . Start your Free Trial

What is Ocata Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Ocata Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2015 was $-0.090. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-26.52 for the trailing ten years ended in Sep. 2015.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-05-05), Ocata Therapeutics's current stock price is $8.47. Ocata Therapeutics's E10 for the quarter that ended in Sep. 2015 was $-26.52. Ocata Therapeutics's Shiller PE Ratio of today is .


Ocata Therapeutics E10 Historical Data

The historical data trend for Ocata Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocata Therapeutics E10 Chart

Ocata Therapeutics Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -30.52

Ocata Therapeutics Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -30.52 -29.57 -28.11 -26.52

Competitive Comparison of Ocata Therapeutics's E10

For the Biotechnology subindustry, Ocata Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocata Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocata Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Ocata Therapeutics's Shiller PE Ratio falls into.



Ocata Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ocata Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2015 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2015 (Change)*Current CPI (Sep. 2015)
=-0.09/100.3915*100.3915
=-0.090

Current CPI (Sep. 2015) = 100.3915.

Ocata Therapeutics Quarterly Data

per share eps CPI Adj_EPS
200512 -17.000 83.032 -20.554
200603 9.000 84.298 10.718
200606 17.000 85.606 19.936
200609 -108.000 85.606 -126.654
200612 -1.000 85.142 -1.179
200703 -49.000 86.640 -56.777
200706 17.000 87.906 19.415
200709 -17.000 87.964 -19.402
200712 11.000 88.616 12.462
200803 -10.000 90.090 -11.144
200806 -4.000 92.320 -4.350
200809 -6.000 92.307 -6.526
200812 5.000 88.697 5.659
200903 -4.000 89.744 -4.475
200906 -6.000 91.003 -6.619
200909 0.000 91.120 0.000
200912 3.000 91.111 3.306
201003 -3.000 91.821 -3.280
201006 0.000 91.962 0.000
201009 0.000 92.162 0.000
201012 -2.000 92.474 -2.171
201103 0.000 94.283 0.000
201106 0.000 95.235 0.000
201109 -3.000 95.727 -3.146
201112 -1.000 95.213 -1.054
201203 0.000 96.783 0.000
201206 0.000 96.819 0.000
201209 0.000 97.633 0.000
201212 -1.000 96.871 -1.036
201303 0.000 98.209 0.000
201306 0.000 98.518 0.000
201309 -0.250 98.790 -0.254
201312 -0.490 98.326 -0.500
201403 -0.330 99.695 -0.332
201406 -0.550 100.560 -0.549
201409 -0.130 100.428 -0.130
201412 -0.180 99.070 -0.182
201503 -0.200 99.621 -0.202
201506 -0.200 100.684 -0.199
201509 -0.090 100.392 -0.090

Add all the adjusted EPS together and divide 10 will get our e10.


Ocata Therapeutics  (NAS:OCAT) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Ocata Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Ocata Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocata Therapeutics (Ocata Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
Ocata Therapeutics Inc was incorporated in Nevada under the name Two Moon Kachinas Corp. on May 18, 2000. The Company is a biotechnology company, engaged in the development and commercialization of human pluripotent stem cell technology in the field of regenerative medicine. It is actively conducting clinical trials for treating dry age-related macular degeneration and Stargardt's macular degeneration, in addition to several clinical and preclinical programs for other ocular therapies. It also has a preclinical development pipeline in areas outside of ophthalmology, including; autoimmune diseases, inflammatory diseases, and wound healing. Its intellectual property portfolio includes pluripotent human embryonic stem cell, or hESC; induced pluripotent stem cell, or iPSC, platforms; and other cell therapy research programs. It has developed a human photoreceptor progenitor cell. In the U.S., one of the Company's ongoing clinical trials is a Phase 1/2 study for treating dry AMD patients by injection of RPE cells made in culture from an hESC line. It is also conducting Phase 1/2 studies in both the U.S. and the U.K. for the treatment of SMD patients using the RPE cell injections. The Company is conducting three trials in cooperation with retinal surgeons at the top eye hospitals in the U.S. and the U.K. including: Jules Stein Eye Institute (UCLA), Wills Eye Institute, Bascom Palmer Eye Institute (University of Miami) and Massachusetts Eye and Ear Infirmary. As of March 27, 2014, the Company had 46 issued patents and 178 pending patent applications filed, a substantial portion of which pertain to its active product development programs. The Company competes with Pfizer, Regenerative Patch Technologies and the Riken Center for Developmental Biology (Japan), among others. The Company's research and development activities are subject to regulation for safety and efficacy by numerous governmental authorities in the United States and other countries.
Executives
Brian Levy director
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Edward H Myles officer: COO & CFO C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Paul K Wotton director, officer: President and CEO C/O ANTARES PHARMA, INC., 707 EAGLEVIEW BOULEVARD, SUITE 414, EXTON PA 19341
Jooste H Le Roux officer: SVP of Bus Development & CCO C/O NABI BIOPHARMACEUTICALS, 5800 PARK OF COMMERCE BLVD., N.W., BOCA RATON FL 33487
Gregory D Perry director C/O IMMUNOGEN, INC., 830 WINTER ST., WALTHAM MA 02451
Robert Langer director 98 MONTVALE RD, NEWTON MA 02459
Michael D West director AGEX THERAPEUTICS, INC., 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA CA 94501
Pedro Huertas officer: Chief Development Officer 950 WINTER STREET, NORTH, WALTHAM MA 02451
Alan G Walton director C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 385 E. COLORADO BLVD., SUITE 299, PASADENA CA 91101
Robert Peabody director, officer: VP - Grant Administration ONE INNOVATION DRIVE, WORCHESTER MA 01605

Ocata Therapeutics (Ocata Therapeutics) Headlines

No Headlines